Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$30.17 USD
-1.04 (-3.33%)
Updated May 31, 2024 04:00 PM ET
After-Market: $30.15 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
Corcept Therapeutics Incorporated [CORT]
Reports for Purchase
Showing records 21 - 40 ( 223 total )
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Optimized Entry and Exit Levels for CORT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Multiple Clinical Data Readouts Expected in 2024; PT Up To $34; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Korlym Revenue Higher Than Expected; Key Catalysts Center on Relacorilant; New $32 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Miricorilant NASH Data Could be the Next Catalyst; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Cushing?s Syndrome Franchise to Remain Strong in 2023 and Beyond; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department